Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03830866 · ClinicalTrials.gov registry record · Phase 3
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 770
- Enrollment target
NCT03830866 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 770 participants.
The verdict
NCT03830866, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 770 participants
- Enrollment target
Study Summary
This is a randomized, multi-center, double-blind, placebo-controlled, global, Phase III study to determine the efficacy and safety of durvalumab + Chemoradiotherapy versus Chemoradiotherapy alone as treatment in Women With Locally Advanced Cervical Cancer
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- BIOLOGICAL Durvalumab
- RADIATION external beam radiation therapy (EBRT) + brachytherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 770 participants |
| Start Date | 2019-02-15 |
| Est. Completion | 2023-07-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03830866
The ClinicalTrials.gov registry entry for NCT03830866 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 770 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT03830866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03830866 about?
NCT03830866 is a clinical study titled "Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)". This is a randomized, multi-center, double-blind, placebo-controlled, global, Phase III study to determine the efficacy and safety of durvalumab + Chemoradiotherapy versus Chemoradiotherapy alone as treatment in Women With Locally Advanced Cervical Cancer
What is the current status of trial NCT03830866?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 770 participants. The study started on 2019-02-15. Estimated completion is 2023-07-03.
What interventions are being tested in trial NCT03830866?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Durvalumab (BIOLOGICAL), external beam radiation therapy (EBRT) + brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT03830866?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.